Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...

Swiss pharma giant Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic ...

Novartis, whose US headquarters is based in East Hanover, has entered into an agreement to acquire Avidity Biosciences, Inc.

The Swiss drugmaker on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash ...

The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody oligonucleotide conjugates.

Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy ...

Novartis has signed an agreement for the acquisition of all the outstanding shares of US-based Avidity Biosciences.

By Bhanvi Satija LONDON (Reuters) -Swiss drugmaker Novartis is exploring options to add more medicines to its ...

Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases; ...

Novartis "can never be done" when it comes to major acquisitions in its sector as it always needs to look for the next "great ...

Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion  Avidity ...

Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc) Core operating income margin 1 was ...